恩格列净在射血分数降低心衰中获益不受基线收缩压影响
EMPEROR-Reduced试验事后分析纳入3730例射血分数降低心衰患者,按基线收缩压分为<110、110-130、>130 mm Hg三组。结果显示基线收缩压不影响恩格列净降低心血管死亡或心衰住院风险及肾脏终点的效果,且收缩压<110 mm Hg患者使用恩格列净未增加症状性低血压发生率。
要点
- 恩格列净在射血分数降低心衰中的心血管和肾脏获益不受基线收缩压水平影响。
- 基线收缩压<110 mm Hg患者使用恩格列净未增加症状性低血压风险。
- 安慰剂组中基线收缩压越低,心血管死亡或心衰住院风险越高(P趋势=0.0015)。
核心结论
- 在EMPEROR-Reduced试验中,恩格列净有效且安全,基线收缩压与恩格列净疗效之间无有意义的交互作用。
研究设计与样本
- EMPEROR-Reduced试验事后分析,3730例射血分数降低心衰患者随机分组,按基线收缩压分为<110 mm Hg(n=928)、110-130 mm Hg(n=1,755)、>130 mm Hg(n=1,047)三组。
主要发现
- 仅安慰剂组中,基线收缩压与心血管死亡或心衰住院风险呈负相关(P趋势=0.0015)。
- 校正安慰剂后,收缩压<110 mm Hg组早期轻微升高,110-130 mm Hg组无变化,>130 mm Hg组轻微降低;4周和12周时组间差异临界显著(交互趋势P=0.05-0.10),后期不显著。
- 基线收缩压不影响恩格列净降低心衰事件或肾脏终点的效果。
- 收缩压<110 mm Hg患者使用恩格列净未增加症状性低血压发生率。
临床怎么用
- 射血分数降低心衰患者使用恩格列净时,无需因基线收缩压偏低而顾虑其心血管和肾脏获益。
- 基线收缩压<110 mm Hg患者使用恩格列净未增加症状性低血压风险,但仍需个体化监测。
局限性
- 本研究为EMPEROR-Reduced试验的事后分析。
- 中位随访16个月,长期交互作用未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood pressure (SBP) is not known. OBJECTIVES: The goal of this study was to evaluate the interplay of SBP and the effects of empagliflozin in EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction). METHODS: Study patients (N = 3,730) were randomly assigned to groups according to SBP at baseline (<110 mm Hg, n = 928; 110-130 mm Hg, n = 1,755; >130 mm Hg, n = 1,047). This study explored the influence of SBP on the effects of empagliflozin on cardiovascular death or HF hospitalization (primary outcome), as well as on total HF hospitalizations, rate of decline in estimated glomerular filtration rate, renal outcomes, and empagliflozin's effects and significance on SBP. RESULTS: Over a median of 16 months considering only patients receiving placebo, baseline SBP and the risk of cardiovascular death or hospitalization for HF (P trend = 0.0015) were inversely related. Corrected for placebo, a slight early increase was observed in SBP at <110 mm Hg, no change at 110-130 mm Hg, and a slight reduction at >130 mm Hg. These between-group differences were of borderline significance (P for interaction trend = 0.05-0.10) after 4 and 12 weeks but were not significant later. SBP at baseline did not influence the effect of empagliflozin to reduce the risk of HF events or renal endpoints. When treated with empagliflozin, patients with SBP <110 mm Hg did not have an increased rate of symptomatic hypotension. CONCLUSIONS: Empagliflozin was effective and safe, with no meaningful interaction between SBP and the effects of empagliflozin in the EMPEROR-Reduced trial. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977).
引用
- Böhm M, Anker SD, Butler J, et al. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. J Am Coll Cardiol. 2021. PMID: 34556320. doi:10.1016/j.jacc.2021.07.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。